Athenex (Athenex) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex ROE % Adjusted to Book Value?

Athenex's ROE % for the quarter that ended in Dec. 2022 was -1,491.07%. Athenex's PB Ratio for the quarter that ended in Dec. 2022 was N/A. Athenex's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was N/A.

Athenex ROE % Adjusted to Book Value Historical Data

The historical data trend for Athenex's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex ROE % Adjusted to Book Value Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-16.79

-11.41

-13.82

-59.05

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-140.40	-64.09	-127.54	-250.19	-

Competitive Comparison of Athenex's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Athenex's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Athenex's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Athenex's ROE % Adjusted to Book Value falls into.

Athenex ROE % Adjusted to Book Value Calculation

Athenex's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-463.54%	/	N/A
	=	N/A

Athenex's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-1,491.07%	/	N/A
	=	N/A

Athenex ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Athenex's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (Athenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Executives

Jinn Wu	director	107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam	director, officer: CEO and Chairman of the Board
Joe Annoni	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook	officer: See Remarks	C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang	officer: Pres Cell Therapy, VP Corp Dev	C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan	director, officer: EVP, Chief Medical Officer	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski	officer: Chief Scientific Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams	officer: Interim Chief Acct Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell	director	3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo	officer: President, China	3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok	director	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203